DK2924052T3 - Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme - Google Patents
Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme Download PDFInfo
- Publication number
- DK2924052T3 DK2924052T3 DK13857338.1T DK13857338T DK2924052T3 DK 2924052 T3 DK2924052 T3 DK 2924052T3 DK 13857338 T DK13857338 T DK 13857338T DK 2924052 T3 DK2924052 T3 DK 2924052T3
- Authority
- DK
- Denmark
- Prior art keywords
- dll4
- vegfr
- pharmaceutical composition
- target antibody
- antibody targeted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20120132431 | 2012-11-21 | ||
| PCT/KR2013/010589 WO2014081202A1 (ko) | 2012-11-21 | 2013-11-20 | Vegfr-2와 dll4를 표적으로 하는 이중표적항체 및 이를 포함하는 약학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2924052T3 true DK2924052T3 (da) | 2019-09-30 |
Family
ID=50776314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13857338.1T DK2924052T3 (da) | 2012-11-21 | 2013-11-20 | Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9963512B2 (da) |
| EP (1) | EP2924052B1 (da) |
| JP (1) | JP6144771B2 (da) |
| KR (1) | KR101569083B1 (da) |
| CN (1) | CN104870476B (da) |
| AU (1) | AU2013348570B2 (da) |
| CA (1) | CA2892193C (da) |
| DK (1) | DK2924052T3 (da) |
| ES (1) | ES2744267T3 (da) |
| WO (1) | WO2014081202A1 (da) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2924052T3 (da) | 2012-11-21 | 2019-09-30 | Pharmabcine Inc | Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme |
| WO2015200905A2 (en) | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| CN107660214B (zh) | 2015-01-08 | 2022-02-08 | 根马布股份公司 | 针对cd3和cd20的双特异性抗体 |
| FI3322727T3 (fi) | 2015-07-15 | 2026-03-17 | Genmab As | Humanisoituja tai kimeerisiä CD3-vasta-aineita |
| CN105267953B (zh) * | 2015-09-15 | 2018-08-31 | 浙江大学 | Dll4细胞因子在制备治疗暴发性肝功能衰竭药剂中的应用 |
| US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| BR112019000512A2 (pt) | 2016-07-14 | 2019-04-24 | Genmab A/S | anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit |
| LT3592769T (lt) | 2017-03-09 | 2024-08-26 | Genmab A/S | Antikūnai, atpažįstantys pd-l1 |
| CN119285787A (zh) | 2017-03-31 | 2025-01-10 | 健玛保控股有限公司 | 双特异性抗cd37抗体、单克隆抗cd37抗体及其使用方法 |
| KR20250020679A (ko) | 2017-08-04 | 2025-02-11 | 젠맵 에이/에스 | Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도 |
| CN107540747B (zh) * | 2017-08-09 | 2020-01-24 | 苏州大学附属儿童医院 | 抗人dll4单克隆抗体6f12 |
| CA3092588A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| CN112055718A (zh) * | 2018-03-19 | 2020-12-08 | 药物抗体公司 | 抗vegfr-2抗体 |
| JP7457007B2 (ja) | 2018-09-19 | 2024-03-27 | ラヴァ・セラピューティクス・エヌ・ヴイ | 二重作用ＣＤ１ｄ免疫グロブリン |
| AU2019354105A1 (en) | 2018-10-04 | 2021-04-29 | Genmab Holding B.V. | Pharmaceutical compositions comprising bispecific anti-CD37 antibodies |
| CN113454111A (zh) | 2018-11-06 | 2021-09-28 | 健玛保 | 抗体配制剂 |
| CN109666073B (zh) * | 2018-12-28 | 2022-02-01 | 中国药科大学 | 一种抗人dll4和抗人vegf双特异性抗体及其制备与应用 |
| WO2020159368A1 (en) | 2019-02-01 | 2020-08-06 | Lava Therapeutics B.V. | Novel cd40-binding antibodies |
| NL2022494B1 (en) | 2019-02-01 | 2020-08-19 | Lava Therapeutics B V | Novel CD40-binding antibodies |
| EP3792283A1 (en) | 2019-09-16 | 2021-03-17 | Lava Therapeutics B.V. | Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021155916A1 (en) | 2020-02-04 | 2021-08-12 | BioNTech SE | Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137 |
| KR20220154757A (ko) | 2020-03-18 | 2022-11-22 | 젠맵 에이/에스 | B7h4에 결합하는 항체 |
| KR20230008775A (ko) | 2020-05-08 | 2023-01-16 | 젠맵 에이/에스 | Cd3 및 cd20에 대한 이중특이적 항체 |
| CN116323667A (zh) | 2020-07-08 | 2023-06-23 | 拉法医疗股份有限公司 | 结合PSMA和γ-δT细胞受体的抗体 |
| WO2022029011A1 (en) | 2020-08-06 | 2022-02-10 | BioNTech SE | Binding agents for coronavirus s protein |
| CN116437956A (zh) | 2020-09-10 | 2023-07-14 | 健玛保 | 用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体 |
| WO2022053654A1 (en) | 2020-09-10 | 2022-03-17 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| MX2023006832A (es) | 2020-12-10 | 2023-08-22 | Lava Therapeutics N V | Anticuerpos que se unen a receptores de linfocitos t gamma-delta. |
| WO2022180271A1 (en) | 2021-02-26 | 2022-09-01 | LAVA Therapeutics N.V. | Antibodies that bind CD123 and gamma-delta T cell receptors |
| KR20240004949A (ko) | 2021-05-07 | 2024-01-11 | 젠맵 에이/에스 | B7h4 및 cd3에 결합하는 이중특이적 항체를 포함하는 제약 조성물 |
| BR112023027006A2 (pt) | 2021-06-21 | 2024-03-12 | BioNTech SE | Método para reduzir ou prevenir a progressão de um tumor ou tratar um câncer em um sujeito, e, agente de ligação |
| KR20240055002A (ko) | 2021-09-13 | 2024-04-26 | 얀센 바이오테크 인코포레이티드 | 암 치료를 위한 CD33 x Vδ2 다중특이성 항체 |
| AR127298A1 (es) | 2021-10-08 | 2024-01-10 | Genmab As | Anticuerpos que se unen a cd30 y cd3 |
| JP2024538958A (ja) | 2021-10-21 | 2024-10-28 | ラヴァ・セラピューティクス・エヌ・ヴイ | ガンマデルタｔ細胞活性化抗体の使用 |
| KR20230109854A (ko) | 2022-01-14 | 2023-07-21 | 주식회사 파멥신 | 항-vegfr2(kdr) 개량 항체를 포함하는 융합단백질 및 이의 용도 |
| WO2023174521A1 (en) | 2022-03-15 | 2023-09-21 | Genmab A/S | Binding agents binding to epcam and cd137 |
| EP4285926A1 (en) | 2022-05-30 | 2023-12-06 | LAVA Therapeutics N.V. | Combination treatment for chronic lymphocytic leukemia |
| EP4292610A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Variant antibodies that bind gamma-delta t cell receptors |
| EP4292609A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Compositions comprising antibodies that bind gamma-delta t cell receptors |
| NL2032398B1 (en) | 2022-07-06 | 2024-01-23 | Academisch Ziekenhuis Leiden | Bispecific antibody and uses thereof |
| CN115364282A (zh) * | 2022-09-05 | 2022-11-22 | 东莞市人民医院 | 双功能血管支架及其制备方法 |
| EP4688851A1 (en) | 2023-03-27 | 2026-02-11 | LAVA Therapeutics N.V. | Nectin-4 binding agents and methods of use |
| EP4438624A1 (en) | 2023-03-27 | 2024-10-02 | LAVA Therapeutics N.V. | Antibodies that bind nectin-4 and gamma-delta t cell receptors |
| TW202506178A (zh) | 2023-04-05 | 2025-02-16 | 丹麥商珍美寶股份有限公司 | 包含與ｃｄ３０和ｃｄ３結合之抗體之醫藥組成物 |
| TW202509077A (zh) | 2023-06-30 | 2025-03-01 | 丹麥商珍美寶股份有限公司 | 與纖維母細胞活化蛋白α及死亡受體４結合之抗體 |
| WO2025012118A2 (en) | 2023-07-07 | 2025-01-16 | LAVA Therapeutics N.V. | 5t4 binding agents and methods of use |
| TW202519261A (zh) | 2023-07-27 | 2025-05-16 | 荷蘭商拉法醫療公司 | 用於治療癌症之結合γ-δ T細胞受體之抗體 |
| WO2025056180A1 (en) | 2023-09-15 | 2025-03-20 | BioNTech SE | Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists |
| WO2026078231A1 (en) | 2024-10-11 | 2026-04-16 | T-Therapeutics Limited | Soluble non-aggregating immune ligand |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
| PT1916001E (pt) | 2002-03-04 | 2011-07-18 | Imclone Llc | Anticorpos humanos específicos para kdr e suas utilizações |
| KR100883430B1 (ko) | 2007-06-13 | 2009-02-12 | 한국생명공학연구원 | 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도 |
| AU2008289462B2 (en) * | 2007-08-23 | 2014-01-23 | The Trustees Of Columbia University In The City Of New York | Compositions of humanized notch fusion proteins and methods of treatment |
| US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| KR20110016959A (ko) * | 2008-06-03 | 2011-02-18 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| KR101224468B1 (ko) * | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
| JP2014500712A (ja) | 2010-11-02 | 2014-01-16 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
| DK2924052T3 (da) | 2012-11-21 | 2019-09-30 | Pharmabcine Inc | Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme |
-
2013
- 2013-11-20 DK DK13857338.1T patent/DK2924052T3/da active
- 2013-11-20 CN CN201380065951.0A patent/CN104870476B/zh not_active Expired - Fee Related
- 2013-11-20 EP EP13857338.1A patent/EP2924052B1/en active Active
- 2013-11-20 WO PCT/KR2013/010589 patent/WO2014081202A1/ko not_active Ceased
- 2013-11-20 JP JP2015543969A patent/JP6144771B2/ja not_active Expired - Fee Related
- 2013-11-20 KR KR1020130141451A patent/KR101569083B1/ko not_active Expired - Fee Related
- 2013-11-20 CA CA2892193A patent/CA2892193C/en active Active
- 2013-11-20 AU AU2013348570A patent/AU2013348570B2/en not_active Ceased
- 2013-11-20 US US14/443,617 patent/US9963512B2/en not_active Expired - Fee Related
- 2013-11-20 ES ES13857338T patent/ES2744267T3/es active Active
-
2018
- 2018-03-14 US US15/920,751 patent/US10155817B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013348570A1 (en) | 2015-06-11 |
| US9963512B2 (en) | 2018-05-08 |
| KR101569083B1 (ko) | 2015-11-16 |
| CA2892193A1 (en) | 2014-05-30 |
| AU2013348570B2 (en) | 2017-01-12 |
| US20150315277A1 (en) | 2015-11-05 |
| ES2744267T3 (es) | 2020-02-24 |
| CA2892193C (en) | 2018-06-19 |
| EP2924052B1 (en) | 2019-07-17 |
| US10155817B2 (en) | 2018-12-18 |
| CN104870476A (zh) | 2015-08-26 |
| EP2924052A4 (en) | 2016-06-22 |
| CN104870476B (zh) | 2018-04-13 |
| US20180208660A1 (en) | 2018-07-26 |
| EP2924052A1 (en) | 2015-09-30 |
| KR20140065352A (ko) | 2014-05-29 |
| JP2016505244A (ja) | 2016-02-25 |
| JP6144771B2 (ja) | 2017-06-07 |
| WO2014081202A1 (ko) | 2014-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2729151T3 (da) | Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf | |
| BR112014002621A2 (pt) | anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento | |
| BR112015002738A2 (pt) | composto , e , composição farmacêutica | |
| HUE042192T2 (hu) | VEGF/DLL4-kötõ ágensek és alkalmazásaik | |
| IL238958A0 (en) | Glutamase inhibitors, compositions comprising same and uses thereof | |
| DK2742019T3 (da) | N1-cyklisk amin-n5-substituerede phenylbiguanidderivater og farmaceutisk sammensætning, der omfatter disse | |
| BR112014029403A2 (pt) | conjugados, anticorpo e formulação farmacêutica | |
| BR112014030278A2 (pt) | anticorpo, e, composição. | |
| IL228738B (en) | Antibody against cldn6, a pharmaceutical preparation including it and its use | |
| BR112013023653A2 (pt) | anticorpo biespecífico, método de preparação do anticorpo, e composição farmacêutica | |
| HUE045348T2 (hu) | Fehérje-hatóanyag konjugátumok és eljárás elõállításukra | |
| BR112014009889A2 (pt) | compostos dissubstituídos, compostos e composição farmacêutica | |
| DK2694038T3 (da) | Farmaceutisk sammensætning | |
| DK2699397T3 (da) | Apparater, system og fremgangsmåder til at danne pressede artikler og pressede artikler dannet derved | |
| DK3912642T3 (da) | Modificeret antistof, antistofkonjugat og fremgangsmåde til fremstilling deraf | |
| PT2696848T (pt) | Nanossuspensões de fármaco liofilizadas | |
| IL230662A0 (en) | Indazoles | |
| DK2812000T3 (da) | Flerlaget nikotinholdig farmaceutisk sammensætning | |
| HRP20170928T1 (hr) | Inhibitori kinurenin-3-monooksigenaze, farmaceutski pripravci, i postupci za njihovu upotrebu | |
| BR112015003259A2 (pt) | composto, composição farmacêutica, e, composição de vacina. | |
| LT3406251T (lt) | Piruvatkinazės aktyvatoriai, skirti panaudoti terapijai | |
| IL230838A0 (en) | Pharmaceutical compositions | |
| PT2882440T (pt) | Combinações farmacêuticas compreendendo um inibidor de braf, um inibidor de egfr e opcionalmente um inibidor de pi3k-alfa | |
| BR112013014644A2 (pt) | composição farmacêutica e complexo | |
| IL232035A0 (en) | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof |